Dasatinib and imatinib: How to choose between two drugs for the treatment of chronic myeloid leukemia

In the medical field of treating chronic myeloid leukemia (CML), both dasatinib and imatinib occupy an important position. Although they have the same goal - to inhibit the proliferation of cancer cells, they have unique characteristics in terms of pharmacological mechanisms, drug efficacy performance, drug metabolism and side effects.

1. In-depth comparison of pharmacological mechanisms

Imatinib, as a leader in tyrosine kinase inhibitors, mainly inhibits the growth of cancer cells by inhibiting the activity ofBCR-ABL fusion protein. In addition, it also exerts inhibitory effects on other related tyrosine kinases, such as c-Kit and PDGFR. Dasatinib, on the other hand, exhibits broader activity in inhibiting tyrosine kinases. In addition to BCR-ABL, it also has inhibitory effects on multiple kinases such as Src family kinases and Eph family kinases, thus giving it more comprehensive anti-tumor capabilities.

2. Differences in drug efficacy

Due to its excellent efficacy, imatinib has become the drug of choice for the treatment of CML and is widely used in clinical practice. Most patients achieve durable complete or partial remission with imatinib. However, some patients may develop drug resistance during treatment, at which time dasatinib becomes an important alternative. Compared with imatinib, dasatinib was up to 325 times more effective in vitro against engineered cell lines expressing non-mutated BCR-ABL, demonstrating strong anti-tumor potential in patients resistant to imatinib.

3. Consideration of drug metabolism and side effects

Imatinib and dasatinib are both metabolized in the liver by the enzyme CYP3A4. However, it is worth noting that dasatinib is metabolized faster and has a shorter elimination half-life. This means that in order to maintain effective drug concentrations, dasatinib needs to be administered more frequently. In terms of side effects, both may cause common adverse reactions such as nausea, vomiting, diarrhea and bone marrow suppression. However, due to differences in pharmacology, dasatinib may also cause additional side effects such as fluid retention, cardiovascular problems, and immune dysfunction. Therefore, doctors need to pay special attention to the patient's heart function and fluid balance status when using dasatinib.

4. Highlights of clinical research

In patients with resistance or intolerance to imatinibIn the CA180-034 trial in CML patients, dasatinib demonstrated durable efficacy and safety at a dose of 100 mg once daily. Among them, the 5-year progression-free survival rate (PFS) reached 57%, the overall survival rate (OS) was 78%, and the 5-year cumulative major molecular response rate (MMR) also reached 44%. These data not only demonstrate the important role of dasatinib in first-line CML-CP treatment, but also provide patients with the possibility of achieving faster and deeper therapeutic responses.

In summary, dasatinib and imatinib, as the two major drug options for the treatment of chronic myeloid leukemia, have shown their respective advantages and characteristics in many aspects. When formulating treatment plans, doctors need to comprehensively consider the patient's specific situation, drug resistance, risk of adverse reactions and other factors, and provide patients with individualized treatment suggestions.